http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2434864-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2006-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85ddc7b1dac512972c3693d5d383ca71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4159d49cf4a6d075ed09cfb4593188c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5807b440739309f9c0866a29ee5a69e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72197c8d1265171c14c1825ad745354a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35c2d9f0f6c5a6bb2cf8ffda5610b2a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a2fad11b32e93a57fd1dacbd31ae55b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91894b9849757c239c04281d4a1ba765 |
| publicationDate | 2011-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2434864-C2 |
| titleOfInvention | 4-methyl-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamide salts |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a novel salt - monohydrate of monohydrochloride of 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide, having protein kinase inhibiting properties. The invention also relates to a method of obtaining said compound. The method involves the following steps: (a) merging 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide in form of a free base and hydrochloric acid in methanol in a nitrogen atmosphere; (b) heating the reaction mixture to temperature in the range of approximately 42-50°C; (c) stirring the reaction mixture; (d) filtering the reaction mixture while maintaining temperature higher than 40°C to obtain a transparent solution; (e) cooling the transparent solution to approximately 30°C while stirring in a nitrogen atmosphere; (f) adding an inoculant to the solution; (g) cooling the solution containing the inoculant to approximately 23°C; (h) stirring the solution to obtain a suspension; (i) cooling the obtained suspension to approximately -10°C; (j) stirring the obtained suspension; (k) filtering solid substances, washing the solid substance with cold methanol; and (l) drying the solid substance at approximately 50-55°C and 10-20 torr to obtain the end product. n EFFECT: monohydrate of monohydrochloride of said compound has high solubility compared to a base and hydrochloride salt and has high bioavailability in vivo compared to said compounds. n 4 cl, 17 tbl, 11 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2551359-C9 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2605551-C2 |
| priorityDate | 2005-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.